A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Phase 3
Completed
NCT05899816
| Condition | Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Amgen |
|---|
| Status | Completed |
|---|
| Enrollment | 221 participants |
|---|
| Interventions | Rocatinlimab |
|---|
| Start date | Jun 7, 2023 |
|---|
| Completion date | Aug 26, 2024 |
|---|
| Results posted | Jul 23, 2026 |
|---|
Summary
The primary objectives of this study are to: * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 * estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24
Percentage of Participants With a Positive Anti-tetanus Response at Week 24
Week 20 to Week 24 · percentage of participants
| Placebo | 92.3 percentage of participants |
|---|
| Rocatinlimab | 87.6 percentage of participants |
|---|
| Risk Difference (RD) | -4.7 (95% CI -13.5–5.9) |
|---|
Percentage of Participants With a Positive Anti-meningococcal Response at Week 24
Week 20 to Week 24 · percentage of participants
| Placebo | 53.2 percentage of participants |
|---|
| Rocatinlimab | 52.5 percentage of participants |
|---|
| Risk Difference (RD) | -0.7 (95% CI -18.3–17.1) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.